Agreed. The damage has been done!
I’d also question the technology to a large extent. If it was really groundbreaking we would have seen regulatory agencies jumping on it and more importantly many investment groups and big pharma lining up to get a piece of the pie. In fact, they ran as far away as possible from LP and the team after May 2022 TLD presentation. No one is interested. So more than 3 years later, LP continues to dilute at lower share price almost every month. That last was at .22. We will be in teens come next month.
MHRA (the most supportive of NWBO) has taken over 20 months and there is no indication that a decision is coming anytime soon. This is extremely unusual and concerning. The MHRA is waiting on NWBO to address their concerns for many months now. 5 years since data lock, and even a supportive agency like UK have raised serious issues with it.
Market Data 
Markets 
